Jan 7, 2025, 16:22
David Gandara: FDA rejects SQ Amivantamab application
David Gandara, Co-Director-Center for Experimental Therapeutics and a professor at UC Davis Comprehensive Cancer Center, shared a post on X:
“FDA rejects SQ Amivantamab application. This is one of these “What in the World moments”. The rejection “unrelated to formulation, efficacy or safety”! The “Why” is a mystery, hopefully resolved soon. After all, this much needed re-formulation is for the benefit of patients.”
David Gandara is the Co-Director-Center for Experimental Therapeutics and a professor at UC Davis Comprehensive Cancer Center. His research interests focus on developmental therapeutics of new anti-cancer agents as well as preclinical modeling and clinical research in lung cancer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 13, 2025, 09:23
Feb 13, 2025, 09:17
Feb 13, 2025, 09:12
Feb 13, 2025, 09:10
Feb 13, 2025, 09:06
Feb 13, 2025, 08:58
Feb 13, 2025, 08:53
Feb 13, 2025, 08:52
Feb 13, 2025, 08:16